High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements

High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements — Trials · CancerIndex

Clinical trials

Registered studies

16 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 11
Recruiting: 4
Ph III recruiting: 0
Growth YoY: —
Industry share: 9%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (2)

clinicaltrialsPublishedShowing 1–4 of 4 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06536049	Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma	recruiting	Phase 1 / Phase 2	38	Yazeed SawalhaOTHER	1	Aug 25, 2026	clinicaltrials
NCT05755087	Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma	recruiting	Phase 1	18	Lapo AlinariOTHER	1	Feb 27, 2026	clinicaltrials
NCT04323956